AnaptysBio, Inc. Common Stock

ANAB

AnaptysBio, Inc. (ANAB) is a biotechnology company focused on developing therapeutic antibodies for immune-related conditions. Founded in 2005 and based in San Diego, California, the company utilizes innovative antibody discovery and engineering technologies to create novel biologics targeting inflammatory and immuno-oncology diseases. Its pioneering platform aims to address unmet medical needs through antibody therapeutics.

$58.00 +3.85 (7.11%)
🚫 AnaptysBio, Inc. Common Stock does not pay dividends

Company News

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim
GlobeNewswire Inc. • Na • April 24, 2026

A Delaware Chancery Court dismissed Tesaro's (GSK subsidiary) anticipatory breach of contract claim against AnaptysBio, rejecting requests for royalty reductions on Jemperli. The ruling affirms Anaptys has not repudiated the collaboration agreement and validates the company's efforts to protect its contractual rights. A trial is scheduled for Jul...

Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
GlobeNewswire Inc. • Na • January 8, 2026

AnaptysBio filed a motion to dismiss Tesaro's anticipatory breach of contract claim in Delaware Chancery Court regarding their Collaboration Agreement over royalties from Jemperli (dostarlimab). Anaptys claims it sought good faith discussions to resolve alleged breaches by Tesaro and GSK, but Tesaro initiated a lawsuit without notice. The court i...

GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties
Benzinga • Vandana Singh • November 21, 2025

GSK's subsidiary Tesaro has filed a lawsuit against AnaptysBio in Delaware Chancery Court, alleging breach of a license agreement for the cancer drug Jemperli, and seeking to protect its royalty rights.

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
GlobeNewswire Inc. • Anaptysbio • November 21, 2025

AnaptysBio filed a legal complaint in Delaware Chancery Court against Tesaro and GSK, alleging material breaches of their Collaboration Agreement, specifically related to PD-1 antagonist research and commercial efforts for the drug Jemperli.

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga • Benzinga Staff Writer • September 29, 2025

Multiple health care stocks experienced significant price movements during Monday's after-market trading session, with some companies seeing notable gains while others experienced declines.

Related Companies